We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Labcorp Gears Up to Report Q1 Earnings: What's in Store?
Read MoreHide Full Article
Key Takeaways
Labcorp is set to report Q1 2026 results on April 30, with revenues seen rising 4.7% year over year.
LH's Dx segment likely gained from acquisitions, partnerships and expanded test offerings.
LH is leveraging AI, automation, and new testing solutions to boost efficiency and expand diagnostics access.
Labcorp Holdings Inc. (LH - Free Report) , or Labcorp, is slated to report its first-quarter 2026 results on April 30, before the market opens.
In the last reported quarter, the company reported adjusted earnings of $4.07, surpassing the Zacks Consensus Estimate by 3.04%. Labcorp outpaced estimates in each of the trailing four quarters, the average surprise being 3.07%.
Q1 Estimates for LH
The Zacks Consensus Estimate for Labcorp’s first-quarter 2026 revenues is pegged at $3.50 billion. This suggests a 4.7% rise from the year-ago reported figure.
The Zacks Consensus Estimate for EPS indicates an improvement of 6.5% to $4.09.
Estimate Revision Trend Ahead of Labcorp’s Q1 Earnings
Estimates for Labcorp’s first-quarter earnings have dropped 1 cent to $4.09 in the past 30 days.
Here’s a quick look at the company’s performance leading up to this announcement.
What’s Shaping Labcorp’s Q1 Outcome?
Revenues in the Diagnostics Laboratories (Dx) segment are expected to have been supported by robust organic growth as well as contributions from acquisitions. The company’s partnerships with health systems and regional and local laboratories over the past several years have driven more than $1 billion in revenues while expanding access to its broad portfolio of routine and specialty testing. In February 2026, Labcorp completed the acquisition of select assets of Empire City Laboratories and signed a multi-year partnership agreement with SOMOS. It also announced an expanded collaboration with PathAI to deploy the FDA-cleared, AISight Dx digital pathology platform across its national network of anatomic pathology labs and hospital collaborations.
Other recent developments include the acquisition of select outreach assets from Community Health Systems and select anatomic pathology assets from Incyte Diagnostics. All these factors are expected to favorably impact Labcorp’s first-quarter results.
An expanding test menu in strategic and high-growth areas, including oncology, women's health, neurology and autoimmune disease, may have been a key growth driver. Recent launches include the first FDA-cleared blood test for Alzheimer's disease assessment in the primary care setting. The company also expanded access to molecular residual disease (MRD) testing for stage I–III breast cancer, stage I–IIIA non-small cell lung cancer and stage III colon cancer to help detect recurrence earlier than traditional imaging. Labcorp’s oncology testing lineup now spans more than 450 tests across cancer types and stages. The integration of Invitae has further strengthened its genetic testing capabilities. All these trends and developments may have acted as tailwinds to revenue growth.
In the first quarter of 2026, the company is also likely to have experienced strong momentum in its Consumer Health business. The Labcorp OnDemand platform offers more than 200 biomarkers in categories like men's and women's health, cancer screenings, sexual health and longevity.
The Zacks Consensus Estimate indicates a 4.6% year-over-year increase in the Dx segment’s revenues.
Within the Biopharma Laboratory Services (“BLS”) segment,Labcorp has likely benefited from the solid performance in Central Laboratories. Growing utilization of specialty testing in clinical trials may have been a key driver in the business.
During fourth-quarter 2025, the company started taking streamlining actions within Early Development, which are expected to reduce annual revenues by $50 million while increasing operating income. Against this backdrop, revenues in the first quarter may have been weighed down.
The Zacks Consensus Estimate projects BLS revenues will grow 3.5% year over year.
Labcorp may have continued to leverage science and technology to drive growth and improve efficiency across operations. AI and automation are already being applied to areas such as pathology, cytology and microbiology. In January 2026, the company agreed to implement Roche’s cobas Mass Spec solution into routine clinical practice, helping speed up turnaround times, improving accuracy and expanding access to advanced diagnostics. The Labcorp Test Finder, developed with Amazon Web Services, helps improve test selection for providers and health systems.
Disciplined expense management and continued execution of the LaunchPad cost-saving initiative are likely to have supported Labcorp’s bottom-line performance in the first quarter of 2026.
Earnings Whispers for Labcorp
Per our proven model, stocks with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), along with a positive Earnings ESP, have a higher chance of beating estimates, which is not the case here, as you can see below:
Earnings ESP: Labcorp has an Earnings ESP of -0.46%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Here are some medical stocks worth considering, as these have the right combination of elements to post an earnings beat this time:
Agenus (AGEN - Free Report) has an Earnings ESP of +7.69% and a Zacks Rank #1. The company is expected to release first-quarter 2026 results soon.
In the trailing four quarters, AGEN delivered an average surprise of 31.42%. The Zacks Consensus Estimate implies that the company’s first-quarter EPS will increase 289.3% from the year-ago quarter’s figure.
10x Genomics (TXG - Free Report) has an Earnings ESP of +75.88% and a Zacks Rank #1. The company is slated to release first-quarter 2026 results on May 7.
TXG’s earnings beat estimates in each of the trailing four quarters, the average surprise being 62.53%. The Zacks Consensus Estimate suggests that TXG’s first-quarter EPS will rise 30.6% from the year-ago reported figure.
The Ensign Group (ENSG - Free Report) has an Earnings ESP of +1.12% and a Zacks Rank #2. The company is expected to release first-quarter 2026 results soon.
ENSG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 2.93%. The Zacks Consensus Estimate for the company’s first-quarter EPS calls for an increase of 17.8% from the year-ago quarter’s figure.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Labcorp Gears Up to Report Q1 Earnings: What's in Store?
Key Takeaways
Labcorp Holdings Inc. (LH - Free Report) , or Labcorp, is slated to report its first-quarter 2026 results on April 30, before the market opens.
In the last reported quarter, the company reported adjusted earnings of $4.07, surpassing the Zacks Consensus Estimate by 3.04%. Labcorp outpaced estimates in each of the trailing four quarters, the average surprise being 3.07%.
Q1 Estimates for LH
The Zacks Consensus Estimate for Labcorp’s first-quarter 2026 revenues is pegged at $3.50 billion. This suggests a 4.7% rise from the year-ago reported figure.
The Zacks Consensus Estimate for EPS indicates an improvement of 6.5% to $4.09.
Estimate Revision Trend Ahead of Labcorp’s Q1 Earnings
Estimates for Labcorp’s first-quarter earnings have dropped 1 cent to $4.09 in the past 30 days.
Here’s a quick look at the company’s performance leading up to this announcement.
What’s Shaping Labcorp’s Q1 Outcome?
Revenues in the Diagnostics Laboratories (Dx) segment are expected to have been supported by robust organic growth as well as contributions from acquisitions. The company’s partnerships with health systems and regional and local laboratories over the past several years have driven more than $1 billion in revenues while expanding access to its broad portfolio of routine and specialty testing. In February 2026, Labcorp completed the acquisition of select assets of Empire City Laboratories and signed a multi-year partnership agreement with SOMOS. It also announced an expanded collaboration with PathAI to deploy the FDA-cleared, AISight Dx digital pathology platform across its national network of anatomic pathology labs and hospital collaborations.
Other recent developments include the acquisition of select outreach assets from Community Health Systems and select anatomic pathology assets from Incyte Diagnostics. All these factors are expected to favorably impact Labcorp’s first-quarter results.
Labcorp Holdings Inc. Price and EPS Surprise
Labcorp Holdings Inc. price-eps-surprise | Labcorp Holdings Inc. Quote
An expanding test menu in strategic and high-growth areas, including oncology, women's health, neurology and autoimmune disease, may have been a key growth driver. Recent launches include the first FDA-cleared blood test for Alzheimer's disease assessment in the primary care setting. The company also expanded access to molecular residual disease (MRD) testing for stage I–III breast cancer, stage I–IIIA non-small cell lung cancer and stage III colon cancer to help detect recurrence earlier than traditional imaging. Labcorp’s oncology testing lineup now spans more than 450 tests across cancer types and stages. The integration of Invitae has further strengthened its genetic testing capabilities. All these trends and developments may have acted as tailwinds to revenue growth.
In the first quarter of 2026, the company is also likely to have experienced strong momentum in its Consumer Health business. The Labcorp OnDemand platform offers more than 200 biomarkers in categories like men's and women's health, cancer screenings, sexual health and longevity.
The Zacks Consensus Estimate indicates a 4.6% year-over-year increase in the Dx segment’s revenues.
Within the Biopharma Laboratory Services (“BLS”) segment,Labcorp has likely benefited from the solid performance in Central Laboratories. Growing utilization of specialty testing in clinical trials may have been a key driver in the business.
During fourth-quarter 2025, the company started taking streamlining actions within Early Development, which are expected to reduce annual revenues by $50 million while increasing operating income. Against this backdrop, revenues in the first quarter may have been weighed down.
The Zacks Consensus Estimate projects BLS revenues will grow 3.5% year over year.
Labcorp may have continued to leverage science and technology to drive growth and improve efficiency across operations. AI and automation are already being applied to areas such as pathology, cytology and microbiology. In January 2026, the company agreed to implement Roche’s cobas Mass Spec solution into routine clinical practice, helping speed up turnaround times, improving accuracy and expanding access to advanced diagnostics. The Labcorp Test Finder, developed with Amazon Web Services, helps improve test selection for providers and health systems.
Disciplined expense management and continued execution of the LaunchPad cost-saving initiative are likely to have supported Labcorp’s bottom-line performance in the first quarter of 2026.
Earnings Whispers for Labcorp
Per our proven model, stocks with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), along with a positive Earnings ESP, have a higher chance of beating estimates, which is not the case here, as you can see below:
Earnings ESP: Labcorp has an Earnings ESP of -0.46%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: The company currently carries a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank stocks here.
Key MedTech Picks
Here are some medical stocks worth considering, as these have the right combination of elements to post an earnings beat this time:
Agenus (AGEN - Free Report) has an Earnings ESP of +7.69% and a Zacks Rank #1. The company is expected to release first-quarter 2026 results soon.
In the trailing four quarters, AGEN delivered an average surprise of 31.42%. The Zacks Consensus Estimate implies that the company’s first-quarter EPS will increase 289.3% from the year-ago quarter’s figure.
10x Genomics (TXG - Free Report) has an Earnings ESP of +75.88% and a Zacks Rank #1. The company is slated to release first-quarter 2026 results on May 7.
TXG’s earnings beat estimates in each of the trailing four quarters, the average surprise being 62.53%. The Zacks Consensus Estimate suggests that TXG’s first-quarter EPS will rise 30.6% from the year-ago reported figure.
The Ensign Group (ENSG - Free Report) has an Earnings ESP of +1.12% and a Zacks Rank #2. The company is expected to release first-quarter 2026 results soon.
ENSG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 2.93%. The Zacks Consensus Estimate for the company’s first-quarter EPS calls for an increase of 17.8% from the year-ago quarter’s figure.